Skip to Main Content

You remember Martin Shkreli. He rocketed to notoriety three years ago when the company he ran, Turing Pharmaceuticals, bought an old anti-infective drug used by AIDS patients and quickly boosted the price of a tablet to $750 from $13.55.  He was widely derided by the pharmaceutical industry as an outlier, although many other companies have regularly trafficked in such maneuvers.

A new analysis, however, suggests these moves are even more common than imagined.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!